Was Griffin Jones a gambler?
Clearly, he was, but that was not all he was.
Although Chen Leyao had a somewhat poor impression of Griffin Jones, she would not deny the strengths he had displayed. At the very least, he was a very rational and talented man, and his conversation often revealed extensive knowledge.
Reining in her impatience, Chen Leyao continued reading the documents and finally understood where Griffin Jones's confidence in investing in Tonghe Pharmaceuticals came from.
At the very bottom of the documents was an exceptionally rigorous analytical report.
In fact, Tonghe Pharmaceuticals had not been entirely without results over the past few years. It had successively filed and published several pharmaceutical technology patents. Without these achievements continually reassuring its shareholders, this research could never have continued until now.
However, these were all rather unremarkable minor patents, scattered and lacking a coherent framework, or offering weak effects and having flaws. They could not generate any economic value.
Yet by organizing and analyzing them, Griffin Jones had actually managed to roughly work out Tonghe Pharmaceuticals' research direction and progress. In the end, he discovered that Tonghe Pharmaceuticals was actually only one step away from success.
And all it would take to cross that final gap was a little money.
Tonghe Pharmaceuticals was researching a proprietary Chinese medicine for lowering blood pressure. It was already almost ninety-nine percent complete, and a solution to the final critical obstacle had actually existed for some time. However, the patented technology was held by another obscure domestic company, and Tonghe Pharmaceuticals, engrossed in its research, had failed to learn of it.
As long as they obtained a patent license from that company, the final obstacle would be readily resolved, and Tonghe Pharmaceuticals' new drug could quickly reach the market.
Moreover, this new drug was